Elevated glycosylated hemoglobin is associated with subclinical neuropathy in neurologically asymptomatic diabetic patients: A prospective study

Journal of Clinical Neurophysiology

Volumn 26, Issue 1, 2009, Pages 50-53

  El Salem, Khalid ^a   Ammari, Fawaz ^a   Khader, Yousef ^a   Dhaimat, Omar ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Diabetes; Glycosylated hemoglobin; Nerve conduction studies; Subclinical neuropathy

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE COURSE; DISEASE DURATION; ELECTROPHYSIOLOGY; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LATENT PERIOD; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDIAN NERVE; MULTIVARIATE ANALYSIS; NERVE CONDUCTION; PERONEUS NERVE; PROSPECTIVE STUDY; RISK FACTOR; SURAL NERVE; ULNAR NERVE; UNIVARIATE ANALYSIS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RISK; STATISTICAL MODEL;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LOGISTIC MODELS; MALE; MEDIAN NERVE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEURAL CONDUCTION; ODDS RATIO; PERONEAL NERVE; PROSPECTIVE STUDIES; SURAL NERVE; ULNAR NERVE;

EID: 65549130065     PISSN: 07360258     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNP.0b013e31819862ee     Document Type: Article

References (29)

1. Albers JW, Brown MB, Sima AAF, Greene DA. Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration and anthropometric factors. Tolrestat study group for the Early Diabetes Intervention Trial. Neurology. 1996;46:85-91.
2. American Diabetes Association American Academy of Neurology (ADAAAN). Consensus statement, report and recommendations of the San Antonio Conference on diabetic neuropathy. Diabetes Care. 1988;11:592-597.
3. American Diabetes Association (ADA). Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl 1):S4-S36.
4. American Diabetes Association (ADA). Standardized measures in diabetic neuropathy (Consensus Statement). Diabetes Care. 1995;18:59-82.
5. Andersen H, Stalberg E, Falck B. F wave latency, the most sensitive nerve conduction parameter in patients with diabetes mellitus. Muscle Nerve. 1997;20:1296-1302. (Pubitemid 27415518)
6. Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J. 2006;82:95-100.
7. Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care. 2005;28:2361-2366. (Pubitemid 41384277)
8. Dyck PJ, Davies JL, Litchy WJ, O'brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997;49:229-239.
9. Dyck PJ, Davies JL, Wilson DM, et al. Risk factors for severity of diabetic polyneuropathy. Intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care. 1999;22:1479-1486.
10. Dyck PJ, Karnes JL, Daube J, et al. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain. 1985;108:861-880. (Pubitemid 16185406)
11. Dyck PJ, Karnes JL, O'brien PC, et al. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42:1164-1170.
12. Dyck PJ, Litchy WJ, Daube JR, et al. Individual attributes versus composite scores of nerve conduction abnormality: sensitivity, reproducibility and concordance with impairment. Muscle Nerve. 2003;27:202-210.
13. Dyck PJ, O'brien PC, Litchy WJ, et al. Monotonicity of nerve tests in diabetes. Subclinical nerve dysfunction precedes diagnosis of polneuropathy. Diabetes Care. 2005;28:2192-2200.
14. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research. Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64:199-207.
15. Gooch C, Podwall D. The diabetic neuropathies. Neurologist. 2004;10:311-322.
16. Graf RJ, Halter JB, Halar E, Porte D Jr. Nerve conduction abnormalities in untreated maturity-onset diabetes: relation to levels of fasting plasma glucose and glycosylated hemoglobin. Ann Intern Med. 1979;90:298-303. (Pubitemid 9153354)
17. Gregersen G. Diabetic neuropathy: influence of age, sex metabolic control and duration of diabetes on motor conduction velocity. Neurology. 1967;17:972-980.
18. Hyllienmark L, Brismar T, Ludvigsson J. Subclinical nerve dysfunction in children and adolescents with IDDM. Diabetologia. 1995;38:685-692.
19. Karsidag S, Morali S, Sargin M, et al. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus. Diabetes Res Clin Pract. 2005;67:211-219. (Pubitemid 40254310)
20. Kimura J. Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice. 2nd ed. Philadelphia: FA Davis, 1989;103-128.
21. Meh D, Denislic M. Subclinical neuropathy in type I diabetic Children. Electroencephalogr Clin Neurophysiol. 1998;109:274-280. (Pubitemid 28274525)
22. Pastore C, Izura V, Geijo-Barrientos E, Dominguez JR. A comparison of electrophysiological tests for the early diagnosis of diabetic neuropathy. Muscle Nerve. 1999;22:1667-1673.
23. Rutkove SB, Kothari MJ, Raynor EM, et al. Sural/radial amplitude ratio in the diagnosis of mild axonal neuropathy. Muscle Nerve. 1997;20:1236-1241.
24. Sari R, Balci MK. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc. 2005;97:1113-1118. (Pubitemid 41098538)
25. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006;295:1688-1697.
26. Service FJ, Rizza RA, Daube JR, et al. Near normoglycaemia improved nerve conduction and vibration sensation in diabetic neuropathy. Diabetologia. 1985;28:722-727.
27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-853.
29. Young RJ, Ewing DJ, Clarke BF. Nerve function and metabolic control in teenage diabetics. Diabetes. 1983;32:142-147.